MESA LABORATORIES INC /CO/
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $45.7M+7.4% | $42.6M+8.1% | $39.4M+2.2% | $38.6M+10.4% | $34.9M |
| Cost of revenue | $26.2M-11.5% | $29.7M+15.3% | $25.7M+5.3% | $24.4M+19.3% | $20.5M |
| Gross profit | $158.3M+4.9% | $150.9M+13.2% | $133.3M-0.3% | $133.7M+22.6% | $109.1M |
| Selling | $40.8M-2.1% | $41.7M+7.9% | $38.6M+3.2% | $37.4M+32.2% | $28.3M |
| General and administrative, other than impairment of finite-lived intangible assets and goodwill | $78.7M+7.3% | $73.3M+0.6% | $72.9M+0.6% | $72.4M+20.1% | $60.3M |
| Research and development | $20.3M+4.0% | $19.5M+1.1% | $19.3M-5.8% | $20.5M+30.0% | $15.8M |
| Impairment of finite-lived intangible assets | $0 | $0-100.0% | $117.6M | $0 | $0 |
| Impairment of goodwill | $0 | $0-100.0% | $156.9M | $0 | $0 |
| Total operating expense | $139.8M+3.9% | $134.5M-66.8% | $405.3M+210.9% | $130.4M+24.9% | $104.4M |
| Operating income (loss) | $18.5M+13.3% | $16.3M+106.0% | -$272.1M-8295.0% | $3.3M-29.4% | $4.7M |
| Interest expense and amortization of debt issuance costs | $10.7M-9.8% | $11.9M+108.2% | $5.7M+19.4% | $4.8M+22.8% | $3.9M |
| Gain on extinguishment of convertible senior notes | $0+100.0% | -$2.9M | $0 | $0 | — |
| Other (income) expense, net | -$4.2M-399.0% | $1.4M+166.1% | -$2.1M-100.2% | -$1.1M+61.5% | -$2.8M |
| Total nonoperating expense, net | $6.5M-37.4% | $10.4M+190.4% | $3.6M-3.7% | $3.7M+228.8% | $1.1M |
| Earnings (loss) before income taxes | $12.0M+101.5% | $6.0M+102.2% | -$275.6M-70760.7% | -$389K-110.9% | $3.6M |
| Income tax expense (benefit) | $5.3M-33.2% | $7.9M+137.1% | -$21.4M-1522.6% | -$1.3M-177.5% | $1.7M |
| Net income (loss) | $6.7M+440.0% | -$2.0M+99.2% | -$254.2M-27438.3% | $930K-50.3% | $1.9M |
| Basic earnings (loss) per share (in dollars per share) | $1220.00+438.9% | -$360.00+99.2% | -$47200.00-27864.7% | $170.00-52.8% | $360.00 |
| Diluted earnings (loss) per share (in dollars per share) | $1210.00+436.1% | -$360.00+99.2% | -$47200.00-27864.7% | $170.00-51.4% | $350.00 |
| Basic (in shares) | 5.5M+1.7% | 5.4M+0.6% | 5.4M+1.2% | 5.3M+2.1% | 5.2M |
| Diluted (in shares) | 5.6M+2.7% | 5.4M+0.6% | 5.4M+0.5% | 5.4M+0.5% | 5.3M |
| Product [Member] | |||||
| Service [Member] | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Mesa Labs reported FY2026 revenues of $249.1M with 3.4% growth and adjusted operating income of $63.5M, while maintaining cost discipline despite BPD challenges
“I am even more excited today than the day I joined. The Mesa diversified platform has tremendous potential to create shareholder value”
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-10 | 2026-03-10 | Ladiwala Shiraz Shabanali | Director | Purchase | 3,500 | $72.23 | $253K | 8,523 | View | |
| 2026-03-10 | 2026-03-10 | Capone Mark Christopher | Director | Purchase | 1,301 | $76.35 | $99K | 3,429 | View | |
| 2026-03-10 | 2026-03-10 | Tripeny R Tony | Director | Purchase | 1,315 | $76.00 | $100K | 5,398 | View |
Informational purposes only, not investment advice.